Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data

Abstract

PurposeThe aim was to systematically extrapolate the occurrence, risk factors, prognostic characteristics, management and outcome of bone metastases (BM) and skeletal related events (SREs) of breast cancer survivors in the real world clinical setting.MethodsA systematic literature search of PubMed, Web of Science, EMBASE OvidSP and EBSCO Academic Search Complete was conducted. Published prospective and retrospective papers investigating BM and SREs in breast cancer patients in non-trial settings were identified and systematically reviewed.ResultsTwenty-four studies met the inclusion criteria. Incidences of BM based on new diagnosis, length of BM-free interval (BMFI) and number and sites of BM were detected by 17 of 24 studies. Seven studies included in the review were subjected to analyses of risk factors for BM. Developments of SREs regarding the occurrence ratio of total and specific SREs, SERs-free interval (SREFI) and the first-line therapy for SREs were observed in 16 of 24 studies. Out of 5 studies, we extracted uni- and multivariate analysis of risk factor for SREs and out of 16 studies - predictors for survival in breast cancer patients with BM.ConclusionsBM and SREs are common problems in non-trial breast cancer populations. Patient demographics, clinical stage, tumor pathological type, molecular receptors status are significantly risk factors for incidence of BM, SREs and the survival. The unique characteristics of BM and SREs in breast cancer patients should be taken into account in future randomized controlled trials, as to optimize individual treatment options and assure a maximally long good quality of life.

Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity

“…Such early assessment of developing bone metastases would enable patient-specific bone-targeted treatment. However, treatment options for patients with bone metastases are scarce and palliative rather than curative 4,5 . Consequently, the design of novel theranostic compounds which detect and treat bone metastases in cancer patients would overcome this unmet need.…”

Cancer‐ and Chemotherapy‐Induced Musculoskeletal Degradation

“…Specifically, cancers of the breast, prostate, and lung have a high propensity for metastasis to bone, with 73%, 68%, and 36% of patients with advanced cancer developing a bony lesion, respectively . Estrogen‐receptor positive status has been identified as a potential risk for developing breast cancer bone metastases; however, a recent systematic analysis concluded that the primary risk factors for developing bone metastases in women with breast cancer are younger age, greater stage, and larger tumor size at diagnosis, whereas estrogen‐receptor status had no effect on bone metastasis risk . For patients diagnosed with prostate cancer, PSA levels ≥20 ng/mL, a Gleason score ≥8, and locally advanced disease are risk factors for developing bone metastases .…”

A gene expression signature‐based nomogram model in prediction of breast cancer bone metastases

“…Most of bone metastases of BC patients were osteolytic, which could cause skeletal‐related events (SREs) including bone destruction, pathological fractures, hypercalcemia, and spinal cord or nerve root compression . Once bone metastases were diagnosed, the overall survival of BC patients decreased dramatically and median life expectancy dropped to 2‐3 years . Current treatment options for BC bone metastases (BCBM) are seldom curative and are instead mostly palliative .…”